POLARIS is a Phase 2 research trial testing a potential new treatment for BRAFV600-mutant positive melanoma that has spread to the brain. The new treatment is called encorafenib (Braftovi) + binimetinib (Mektovi).
The purpose of this research trial is to determine if high‑dose encorafenib and binimetinib versus standard-dose encorafenib and binimetinib are safe and effective in melanoma that has spread to the brain. The standard dose of encorafenib + binimetinib has been approved by the Therapeutic Goods Association (TGA) in Australia for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation but not for the treatment of melanoma that has spread to the brain.
For more information, visit: https://affinityresearch.com.au/polaris/
